Our findings also showed that levels of phosphorylated ERK and STAT3 increased in proliferative tumor cells suggesting that inhibition of PI3K/AKT pathway activates MAPK and JAK/STA3 survival signaling that could eventually lead to therapeutic resistance. The gene discussed is ARHGEF3; the disease is neoplasm.